Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

World Health Organization, Solid Tumors, Cancer Management +17

REporting recommendations for tumor MARKer prognostic studies (REMARK)

Lisa M. McShane, Douglas G. Altman, Willi Sauerbrei et al. · Breast Cancer Research and Treatment · 2006 · 801 citations

Prognostic Evaluation, Prognostic Biomarkers, Medicine +4

Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

Matthew J. Ellis, Vera J. Suman, Jeremy Hoog et al. · Journal of Clinical Oncology · 2011 · 554 citations

Prognostic factors in 1038 women with metastatic breast cancer

R. Largillier, Jean-­Marc Ferrero, J. Doyen et al. · Annals of Oncology · 2008 · 367 citations · Full text

Metastatic Breast Cancer, Breast Oncology, Medicine +3

Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis

Erich‐Franz Solomayer, Ingo Diel, G. Meyberg et al. · Breast Cancer Research and Treatment · 2000 · 355 citations

Clinical Course, Surgical Oncology, Metastatic Breast Cancer +8